News

Kaléo Enters Into Licensing Agreement With Valeo Pharma For The Canadian Rights to ALLERJECT®(epinephrine injection, USP)

Richmond, Va – Kaléo, a privately held U.S. pharmaceutical company, today announced that

it has entered into a ten-year License, Supply, and Commercialization agreement with Valeo Pharma, a

Canadian pharmaceutical company, for the Canadian rights to ALLERJECT® (epinephrine injection, USP) for the

treatment of severe allergic reactions.

“Patients with life threatening allergies across Canada deserve access to this innovative and potentially

lifesaving product,” said Kaléo President and CEO Ronald Gunn. “Valeo Pharma’s sales force, relationships with

the healthcare community, and commitment to patients make them the ideal partner for ALLERJECT.”

For more information please click here.

Recent News

08/15/2022

ivWatch Extends Its Global Reach Signing Three New Distribution Partners

Newport News, VA, ivWatch, LLC, an innovative IV safety company working to eliminate harm caused by infiltration and extravasation events, announced three new strategic distribution partnerships internationally. Bameco in Austria, Warba Medical Supplies in Kuwait, and Mustafa Sultan Science & Industry Co, LLC in Oman have each signed exclusive agreements to promote, sell, and support

08/15/2022

Registration Now Open for Catalyst Life Sciences Conference

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), announced that registration is open for the Catalyst Life Sciences Conference. The event will be held October 6-7, 2022 at the Omni Hotel in  Richmond, Virginia. This conference is designed for scientists, engineers, entrepreneurs, incubators and biohubs, life science companies, technology transfer

08/13/2022

Kaléo launches government biz unit

Richmond pharma company also hires chief commercial officer.   Richmond-based Kaléo on Thursday announced the formation of a new government business unit to focus on domestic and international procurement of the company’s system to reverse the effect of weaponized opioids as well as to provide access to it for military and civilian stockpiles. Kaléo’s Rapid